51 results
8-K
EX-99
XENE
Xenon Pharmaceuticals Inc
15 Dec 14
Results of Operations and Financial Condition
12:00am
or the first quarter of 2015. Glybera is the first gene therapy product approved in the European Union for the treatment of the orphan disorder lipoprotein … in the European Union and a broad development pipeline and multiple pharmaceutical partnerships, including with Teva and Genentech. For more information
8-K
EX-1.1
XENE
Xenon Pharmaceuticals Inc
30 Nov 23
Entry into a Material Definitive Agreement
4:15pm
, the European Union, His Majesty’s Treasury, or other relevant sanctions authority (collectively, “Sanctions”); nor is the Company or any of its … laws and regulations, including without limitation HIPAA and the European Union General Data Protection Regulation (“GDPR”) (EU 2016/679) (collectively
8-K
EX-1.1
XENE
Xenon Pharmaceuticals Inc
23 Jun 22
Other Events
4:04pm
Security Council, the European Union, Her Majesty’s Treasury, or other relevant sanctions authority (collectively, “Sanctions”); nor is the Company … data privacy and security laws and regulations, including without limitation HIPAA and the European Union General Data Protection Regulation (“GDPR
10-K
fq6hz
12 Mar 15
Annual report
12:00am
10-Q
k8rbazps4ytdo
15 Dec 14
Quarterly report
12:00am
S-1/A
EX-10.4
1uxyc1frruajqu
6 Oct 14
IPO registration (amended)
12:00am
8-K
EX-1.1
xmot7
6 Aug 20
Entry into a Material Definitive Agreement
4:56pm
S-1/A
EX-10.1
brikdu0p5ewxvynr2rk
6 Oct 14
IPO registration (amended)
12:00am
8-K
EX-1.1
h9xcf
5 Nov 19
Entry into a Material Definitive Agreement
4:54pm